{"id":52198,"date":"2025-12-29T20:45:08","date_gmt":"2025-12-29T12:45:08","guid":{"rendered":"https:\/\/flcube.com\/?p=52198"},"modified":"2025-12-29T20:45:09","modified_gmt":"2025-12-29T12:45:09","slug":"transcenta-licenses-hicb-platform-to-eirgenix-for-continuous-biomanufacturing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52198","title":{"rendered":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing"},"content":{"rendered":"\n<p><strong>Transcenta Holding Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6628:HKG\">HKG: 6628<\/a>) announced a <strong>strategic collaboration and non\u2011exclusive licensing agreement<\/strong> with <strong>EirGenix Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6589:TPE\">TPE: 6589<\/a>) granting EirGenix access to its <strong>Highly Intensified Continuous Bioprocessing (HiCB) platform<\/strong> for biologics development and <strong>CDMO services<\/strong>, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Transcenta Holding Limited (06628.HK)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>EirGenix Inc. (6589.TW)<\/td><\/tr><tr><td><strong>Technology Licensed<\/strong><\/td><td>HiCB platform: continuous perfusion, hybrid continuous purification, process documentation, know\u2011how, regulatory support<\/td><\/tr><tr><td><strong>License Scope<\/strong><\/td><td>Non\u2011exclusive, global<\/td><\/tr><tr><td><strong>Use Case<\/strong><\/td><td>EirGenix biologics programs &amp; CDMO client services<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Substantial upfront + milestone payments + royalties on commercial sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-hicb-platform\">Technology Profile: HiCB Platform<\/h2>\n\n\n\n<p><strong>Highly Intensified Continuous Bioprocessing (HiCB)<\/strong> represents a <strong>next\u2011generation manufacturing paradigm<\/strong> designed to replace conventional fed\u2011batch processes:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>HiCB Platform<\/th><th>Conventional Fed\u2011Batch<\/th><th>Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Process Type<\/strong><\/td><td>Continuous perfusion + integrated hybrid purification<\/td><td>Batch\/discrete steps<\/td><td><strong>Uninterrupted production<\/strong><\/td><\/tr><tr><td><strong>Productivity<\/strong><\/td><td>3\u20115x higher cell density\/viability<\/td><td>Limited by batch duration<\/td><td><strong>Higher yields, lower COGS<\/strong><\/td><\/tr><tr><td><strong>Process Control<\/strong><\/td><td>Real\u2011time monitoring &amp; adaptive control<\/td><td>Manual sampling &amp; adjustments<\/td><td><strong>Enhanced consistency, reduced variability<\/strong><\/td><\/tr><tr><td><strong>COGS Reduction<\/strong><\/td><td><strong>30\u201150%<\/strong> vs. fed\u2011batch<\/td><td>Baseline<\/td><td><strong>Improved margins, affordable biologics<\/strong><\/td><\/tr><tr><td><strong>Facility Footprint<\/strong><\/td><td>40\u201160% smaller<\/td><td>Larger scale tanks<\/td><td><strong>Lower CapEx, faster scale\u2011up<\/strong><\/td><\/tr><tr><td><strong>Product Quality<\/strong><\/td><td>Consistent product quality &amp; potency<\/td><td>Batch\u2011to\u2011batch variation<\/td><td><strong>Regulatory advantage, reduced rejections<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Commercial Impact<\/strong>: The platform enables <strong>24\/7 manufacturing<\/strong> with <strong>flexible capacity<\/strong> and <strong>reduced time\u2011to\u2011market<\/strong> for biologics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-continuous-bioprocessing\">Market Context: Continuous Bioprocessing<\/h2>\n\n\n\n<p><strong>Global Biologics CDMO Market<\/strong>: <strong>$25\u201130\u202fbillion<\/strong> (2025), growing at <strong>12\u201114% CAGR<\/strong>, with <strong>continuous manufacturing<\/strong> representing <strong>&lt;5%<\/strong> of installed capacity but <strong>30% of new facility investments<\/strong>.<\/p>\n\n\n\n<p><strong>China CDMO Growth<\/strong>: <strong>$8\u201110\u202fbillion<\/strong> market, driven by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biosimilar wave<\/strong>: 50+ biosimilars in development requiring cost\u2011effective manufacturing<\/li>\n\n\n\n<li><strong>Biologics exports<\/strong>: NMPA\u2011approved facilities seeking global GMP compliance<\/li>\n\n\n\n<li><strong>Cost pressure<\/strong>: NRDL reimbursement cuts forcing COGS optimization<\/li>\n<\/ul>\n\n\n\n<p><strong>Technology Adoption<\/strong>: Only <strong>4\u20115 global players<\/strong> (including <strong>Cytiva, Sartorius<\/strong>) offer integrated continuous platforms; Transcenta\u2019s HiCB is <strong>one of two China\u2011originated platforms<\/strong> with clinical\u2011scale validation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-competitive-moat\">Strategic Rationale &amp; Competitive Moat<\/h2>\n\n\n\n<p><strong>Transcenta\u2019s Positioning<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Monetization<\/strong>: Converts internal R&amp;D capability into <strong>licensing revenue<\/strong> without diluting core pipeline focus<\/li>\n\n\n\n<li><strong>CDMO Market Capture<\/strong>: EirGenix\u2019s <strong>Taiwan\u2011based GMP facility<\/strong> (capacity: 2,000\u202fL single\u2011use bioreactors) becomes <strong>first external adopter<\/strong>, creating <strong>proof\u2011of\u2011concept<\/strong> for broader licensing<\/li>\n\n\n\n<li><strong>Global Validation<\/strong>: EirGenix\u2019s track record of <strong>FDA\/EMA inspections<\/strong> and <strong>20+ biologics partnerships<\/strong> enhances HiCB\u2019s regulatory credibility<\/li>\n<\/ul>\n\n\n\n<p><strong>EirGenix\u2019s Motivation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation<\/strong>: Offers <strong>intensified manufacturing<\/strong> to clients seeking <strong>cost\u2011competitive CDMO services<\/strong><\/li>\n\n\n\n<li><strong>Capacity Utilization<\/strong>: HiCB enables <strong>higher throughput<\/strong> per facility, improving asset efficiency<\/li>\n\n\n\n<li><strong>Client Demand<\/strong>: <strong>70% of EirGenix\u2019s biotech clients<\/strong> have expressed interest in <strong>continuous manufacturing<\/strong> to meet <strong>US\/EU price pressures<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections-amp-upside\">Financial Projections &amp; Upside<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Revenue Stream<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront\/Milestone<\/strong><\/td><td>\u00a550\u201180\u202fmillion<\/td><td>\u00a5100\u2011150\u202fmillion<\/td><td>\u00a550\u2011100\u202fmillion<\/td><\/tr><tr><td><strong>Royalty (net sales)<\/strong><\/td><td>\u2013<\/td><td>\u00a520\u201140\u202fmillion<\/td><td>\u00a5120\u2011180\u202fmillion<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>\u00a550\u201180\u202fM<\/strong><\/td><td><strong>\u00a5120\u2011190\u202fM<\/strong><\/td><td><strong>\u00a5170\u2011280\u202fM<\/strong><\/td><\/tr><tr><td><strong>(US$ equivalent)<\/strong><\/td><td>$7\u201111\u202fM<\/td><td>$17\u201127\u202fM<\/td><td>$24\u201140\u202fM<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Upside Scenarios<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Additional Licensees<\/strong>: Non\u2011exclusive structure allows <strong>2\u20113 more deals<\/strong>; potential <strong>total addressable market<\/strong> of <strong>\u00a51\u20111.5\u202fbillion<\/strong> in licensing revenue by 2030<\/li>\n\n\n\n<li><strong>Platform Expansion<\/strong>: HiCB applicable to <strong>ADCs, bispecifics, mRNA<\/strong>; next\u2011generation upgrades could command <strong>premium pricing<\/strong><\/li>\n\n\n\n<li><strong>Equity Participation<\/strong>: Potential for <strong>minority investment<\/strong> from EirGenix or co\u2011development of <strong>joint\u2011owned biologics<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Transcenta\u2019s licensing revenue, milestone achievements, and EirGenix\u2019s adoption timeline, as well as market projections for continuous bioprocessing. Actual results may differ materially due to technology transfer challenges, competitive responses, and regulatory acceptance of continuous manufacturing platforms..<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,1882,975,4460,181],"class_list":["post-52198","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-eirgenix","tag-hkg-6628","tag-tpe-6589","tag-transcenta"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix Inc. (TPE: 6589) granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics development and CDMO services, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52198\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing\" \/>\n<meta property=\"og:description\" content=\"Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix Inc. (TPE: 6589) granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics development and CDMO services, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52198\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T12:45:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-29T12:45:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing\",\"datePublished\":\"2025-12-29T12:45:08+00:00\",\"dateModified\":\"2025-12-29T12:45:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198\"},\"wordCount\":564,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2905.webp\",\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"EirGenix\",\"HKG: 6628\",\"TPE: 6589\",\"Transcenta\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52198#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52198\",\"name\":\"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2905.webp\",\"datePublished\":\"2025-12-29T12:45:08+00:00\",\"dateModified\":\"2025-12-29T12:45:09+00:00\",\"description\":\"Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix Inc. (TPE: 6589) granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics development and CDMO services, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52198\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2905.webp\",\"width\":1080,\"height\":608,\"caption\":\"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52198#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing - Insight, China&#039;s Pharmaceutical Industry","description":"Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix Inc. (TPE: 6589) granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics development and CDMO services, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52198","og_locale":"en_US","og_type":"article","og_title":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing","og_description":"Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix Inc. (TPE: 6589) granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics development and CDMO services, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.","og_url":"https:\/\/flcube.com\/?p=52198","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T12:45:08+00:00","article_modified_time":"2025-12-29T12:45:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52198#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52198"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing","datePublished":"2025-12-29T12:45:08+00:00","dateModified":"2025-12-29T12:45:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52198"},"wordCount":564,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52198#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp","keywords":["CRO \/ CMO \/ CDMO","EirGenix","HKG: 6628","TPE: 6589","Transcenta"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52198#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52198","url":"https:\/\/flcube.com\/?p=52198","name":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52198#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52198#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp","datePublished":"2025-12-29T12:45:08+00:00","dateModified":"2025-12-29T12:45:09+00:00","description":"Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non\u2011exclusive licensing agreement with EirGenix Inc. (TPE: 6589) granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics development and CDMO services, positioning Transcenta to capture value from its proprietary manufacturing technology across the global biopharma supply chain.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52198#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52198"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52198#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp","width":1080,"height":608,"caption":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52198#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52198"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52198\/revisions"}],"predecessor-version":[{"id":52201,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52198\/revisions\/52201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52200"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}